Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) signs a distribution agreement with Radius for its prostate cancer imaging product in Italy
- Under the agreement, Radius will hold exclusive distribution rights for Illuccix in the country over a three-year period from its approval date
- Radius CEO Mauro Mei says the commercial partnership with Telix will enable it to open the door to state-of-the-art imaging for around 39,000 men diagnosed with prostate cancer each year in Italy
- Telix Pharmaceuticals is up 1.10 per cent, trading at $6.41 at 1:05 pm AEST
Telix Pharmaceuticals (TLX) has signed a distribution agreement for its prostate cancer imaging product.
The exclusive commercial agreement with Bologna-based Radius will see Telix’s investigational imaging product, Illuccix, distributed in the Italian market.
Illuccix has previously been accepted for filing by the FDA in the US and is under priority evaluation by the Australian TGA, while progress has been made on applications for the European Union and Canada.
Under the terms of the agreement, Radius will have exclusive distribution rights for Illuccix in the country over a three-year period from its approval date.
“Partnering with such a capable and patient-centric leader in nuclear medicine aligns with Telix’s mission of helping patients with cancer live longer, better quality lives,” said Richard Valeix, Telix’s President of Europe, Middle East and Africa.
Radius CEO Mauro Mei said the commercial partnership with Telix would enable it to open the door to state-of-the-art imaging for around 39,000 men diagnosed with prostate cancer each year in Italy.
“Given that PSMA imaging represents the latest standard of care for prostate cancer imaging, having recently been included in European and U.S clinical practice guidelines, we are delighted to be adding Illuccix to our nuclear medicine portfolio and look forward to bringing this product to Italian men in need, upon receipt of regulatory approval,” Dr Mei said.
Telix Pharmaceuticals was up 1.10 per cent, trading at $6.41 at 1:05 pm AEST.
